Related Experiment Video

Updated: Nov 2, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Tumor progress intercept by intervening in Caveolin-1 related intercellular communication via ROS-sensitive c-Myc

Xueqing Zhou1, Xuan Liu1, Xiqin Yang1

  • 1College of Pharmaceutical Science, Zhejiang University, Hangzhou, 310058, China.

Biomaterials
|June 15, 2021
PubMed

Insights

This study developed a dual-targeted nanocarrier delivering a c-Myc inhibitor (JQ1) to tumor cells and macrophages. This strategy effectively inhibited tumor growth and metastasis with reduced toxicity.

Area of Science:

  • Oncology
  • Nanomedicine
  • Immunology

Background:

  • Tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) significantly influence tumor progression through cytokine secretion and direct cell communication.
  • Targeting TAMs presents an attractive therapeutic strategy for cancer treatment.
  • The oncogene c-Myc is implicated in various aspects of tumor cell oncogenesis and macrophage activation.

Purpose of the Study:

  • To develop a dual-targeted delivery system for the c-Myc inhibitor JQ1, targeting both tumor cells and TAMs.
  • To investigate the therapeutic potential of this system in inhibiting tumor growth, metastasis, and M2 macrophage polarization.
  • To explore the mechanism by which JQ1 inhibits tumor cell migration mediated by M2 macrophage-derived exosomes.

Main Methods:

  • Construction of a glycolipid nanocarrier (CSOPOSA) with ROS-responsive peroxalate linkages for drug release.
  • Modification of the nanocarrier with Ex 26, a selective sphingosine 1-phosphate receptor 1 (S1PR1) antagonist (Ex 26-CSOPOSA), for dual targeting.
  • Delivery of the c-Myc inhibitor JQ1 via S1PR1, which is overexpressed on tumor cells and TAMs.
  • Assessment of JQ1's effect on tumor cell apoptosis, M2 macrophage polarization, and tumor cell migration induced by exosomes.
  • Investigation of the role of Caveolin-1, lncRNA H19, and miR-107 in exosome-mediated intercellular communication.

Main Results:

  • The Ex 26-CSOPOSA nanocarrier successfully achieved dual-targeted delivery of JQ1.
  • JQ1 induced tumor cell apoptosis and inhibited M2 polarization of macrophages.
  • JQ1 effectively suppressed tumor cell migration induced by M2 macrophage-derived exosomes by disrupting exosome exchange via lncRNA H19 and miR-107.
  • In vivo studies demonstrated significant inhibition of tumor growth and metastasis with reduced systemic toxicity.

Conclusions:

  • The developed dual-targeted delivery strategy using Ex 26-CSOPOSA nanocarriers shows significant potential for effective cancer treatment.
  • This approach offers a promising method for simultaneously targeting tumor cells and TAMs, leading to enhanced therapeutic outcomes.
  • The findings highlight the intricate role of exosome communication in tumor metastasis and provide a novel therapeutic avenue targeting this pathway.
Keywords:
Caveolin-1Drug delivery systemExosomesTumor-associated macrophagesc-Myc

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
790